The ELF score has been well-validated against biopsy-proven fibrosis across a range of chronic liver diseases (CLD) in both adult and pediatric populations. The three direct markers of the ELF test provide complementary information, and the combined score outperforms both the individual markers and simple scores such as APRI or FIB-4.
The performance of the ELF test for liver fibrosis has been well-established in the scientific literature, and ease of testing and interpretation support routine clinical use as an alternative to invasive biopsy.
The Enhanced Liver Fibrosis (ELF™) test is a noninvasive blood (serum) lab test designed to assess levels of three major components directly involved in liver matrix metabolism: hyaluronic acid (HA), procollagen III aminoterminal peptide (PIIINP), and tissue inhibitor of matrix metalloproteinase 1 (TIMP-1). The analytes are automatically measured, and the software calculates and reports a unitless numeric score. Increasing ELF scores are linked to both biopsy-proven fibrosis and prognosis for clinically significant outcomes (Figure 1). |  Figure 1. The ELF™ scoring system |
|
Test specifications
Laboratory capabilities
Search and find publications that we have published.
Please don't hesitate to contact us if you have any questions or other inquiries.
